Jacobs Levy Equity Management Inc. Has $23.35 Million Holdings in DexCom, Inc. $DXCM

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in DexCom by 341.7% during the 1st quarter, owning approximately 341,860 shares valued at $23.3 million.
• Research analysts have lifted DexCom's price targets, with Oppenheimer setting a new objective at $102.00, while multiple analysts maintain a consensus rating of "Moderate Buy".
• DexCom reported a quarterly revenue of $1.16 billion, surpassing estimates, and generated earnings per share of $0.48, indicating a year-over-year increase in revenue by 15.2%.

Jacobs Levy Equity Management Inc. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 341.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 341,860 shares of the medical device company's stock after acquiring an additional 264,459 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.09% of DexCom worth $23,346,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC lifted its position in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the period. Private Trust Co. NA lifted its holdings in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after buying an additional 335 shares during the period. Farther Finance Advisors LLC lifted its holdings in DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after buying an additional 702 shares during the period. Dynamic Advisor Solutions LLC lifted its holdings in DexCom by 34.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after buying an additional 1,333 shares during the period. Finally, Stonebridge Financial Group LLC lifted its stake in shares of DexCom by 944.5% in the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after purchasing an additional 2,909 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of DexCom stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director owned 22,667 shares of the company's stock, valued at $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This represents a 0.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,237 shares of company stock valued at $1,263,480 over the last quarter. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DXCM. UBS Group increased their price target on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Canaccord Genuity Group reissued a "buy" rating and issued a $106.00 target price on shares of DexCom in a research note on Friday, August 1st. The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 target price on the stock. William Blair upgraded shares of DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. Finally, Truist Financial initiated coverage on shares of DexCom in a research report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Stock Up 0.4%

Shares of NASDAQ DXCM traded up $0.31 during mid-day trading on Friday, reaching $76.31. 795,741 shares of the company's stock were exchanged, compared to its average volume of 3,922,925. The firm has a market capitalization of $29.93 billion, a price-to-earnings ratio of 52.98, a PEG ratio of 1.59 and a beta of 1.48. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The business has a fifty day simple moving average of $81.01 and a 200 day simple moving average of $78.80. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business's quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.